Zhejiang Chengyi Pharmaceutical Co. Ltd. Class A

Zhejiang Chengyi Pharmaceutical Co. Ltd. Class A

SSSE:603811
6.52
CNY
0.00
(0.00%)
0.43EPS
16.54P/E
3.20BMarket Cap

Total Valuation

CNY

As of September 30, 2026, Zhejiang Chengyi Pharmaceutical Co. Ltd. Class A carries a market capitalization of 3.20B, placing it among publicly traded companies globally. Its enterprise value stands at 3.06B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap3.20B
Enterprise Value3.06B

Share Statistics

As of September 30, 2026, Zhejiang Chengyi Pharmaceutical Co. Ltd. Class A has 458.23M shares outstanding.

Shares Outstanding458.23M

Valuation Ratios

As of September 30, 2026, Zhejiang Chengyi Pharmaceutical Co. Ltd. Class A trades at a trailing price-to-earnings ratio of 16.54. The price-to-sales ratio is 3.77, and the price-to-book ratio stands at 2.15.

PE Ratio16.54
PS Ratio3.77
PB Ratio2.15
P/TBV Ratio2.22

Enterprise Valuation

As of September 30, 2026, Zhejiang Chengyi Pharmaceutical Co. Ltd. Class A trades at an EV/EBITDA multiple of 14.60 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.69 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 14.60 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 3.06B versus a market cap of 3.20B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales3.69
EV / EBITDA14.60
EV / EBIT14.60

Financial Position

As of September 30, 2026, Zhejiang Chengyi Pharmaceutical Co. Ltd. Class A maintains a current ratio of 2.08, meaning it holds 2.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 3.65, indicating elevated leverage, while an interest coverage ratio of 225.43 demonstrates strong ability to service its debt obligations.

Current Ratio2.08
Quick Ratio0.94
Debt / Equity3.65
Debt / EBITDA0.26
Interest Coverage225.43

Financial Efficiency

CNY

These figures cover the twelve months ended September 30, 2026. The company generates approximately 1.37M in revenue per employee across its workforce of 604.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee1.37M
Employee Count604.00

Taxes

CNY

Over the twelve months ended September 30, 2026, Zhejiang Chengyi Pharmaceutical Co. Ltd. Class A recorded 17.63M in income tax expense. That works out to an effective tax rate of 8.45, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 208.56M, leaving 189.16M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax17.63M
Effective Tax Rate8.45

Stock Price Statistics

CNY

As of the close on November 17, 2026, Zhejiang Chengyi Pharmaceutical Co. Ltd. Class A's stock has declined approximately 21.85% over the past 52 weeks. The 50-day moving average sits at 6.82, while the 200-day moving average is 7.68.

52-Week Price Change-21.85%
50-Day Moving Average6.82
200-Day Moving Average7.68

Income Statement

CNY

Over the twelve months ended September 30, 2026, Zhejiang Chengyi Pharmaceutical Co. Ltd. Class A generated 829.51M in revenue and converted that into 189.16M in net income, yielding earnings per share of 0.43. EBITDA reached 209.55M, while operating income came in at 178.40M.

Revenue829.51M
Gross Profit580.68M
Operating Income178.40M
Pretax Income208.56M
Net Income189.16M
EBITDA209.55M
EBIT209.55M
Earnings Per Share (EPS)0.43

Balance Sheet

CNY

As of September 30, 2026, Zhejiang Chengyi Pharmaceutical Co. Ltd. Class A holds 206.03M in cash and equivalents against 54.72M in total debt, resulting in a net debt position of -146.13M. Total book value stands at 1.49B, with working capital of 236.74M providing operational flexibility.

Cash & Cash Equivalents206.03M
Total Debt54.72M
Net Debt-146.13M
Equity (Book Value)1.49B
Book Value Per Share3.26
Working Capital236.74M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-88.64M

Margins

Over the twelve months ended September 30, 2026, Zhejiang Chengyi Pharmaceutical Co. Ltd. Class A posted a gross margin of 70.00, reflecting its pricing power and cost economics. The operating margin of 21.51 and net profit margin of 22.80 provide insight into operational efficiency.

Gross Margin70.00
Operating Margin21.51
Pretax Margin25.14
Profit Margin22.80
EBITDA Margin25.26

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Zhejiang Chengyi Pharmaceutical Co. Ltd. Class A paid dividends of 0.22 per share. The dividend payout ratio of 51.54 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 5.03, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Zhejiang Chengyi Pharmaceutical Co. Ltd. Class A shareholders.

Dividend Per Share0.22
Payout Ratio51.54
Shareholder Yield5.03

Stock Splits

Zhejiang Chengyi Pharmaceutical Co. Ltd. Class A's most recent stock split took place on June 26, 2026 with a 5:7 split ratio.

Last Split Date6/26/2026
Split Ratio5:7

Scores

As of September 30, 2026, Zhejiang Chengyi Pharmaceutical Co. Ltd. Class A has an Altman Z-Score of 8.68, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score8.68